
Alible Pharmaceutical Private Limited
About Alible Pharmaceutical Private Limited
Data last updated:
Alible Pharmaceutical Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 August 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24290MH2021PTC365379.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Shivaji Ramesh Zodage (Managing Director) and Dilip Bajarang Shinde.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D/5 Ashtavinayak Chs Plot No 4 Panchpakhadi Savarkar Nagar, Thane, Maharashtra, India – 400606.
As per the financials filed for FY 2025, the company reported a revenue of ₹11.22 Lakh, a growth of 10% compared to the previous year. For the same year it recorded a net loss of ₹38,254 (net margin -3.4%) and EBITDA of -₹34,574 (EBITDA margin -3.1%). Revenue has grown at a compounded annual rate (CAGR) of 210% over three years.
Company details
Contact details
Alible Pharmaceutical Private Limited's registered office is in Thane, Maharashtra.
- Registered AddressD/5 Ashtavinayak Chs Plot No 4 Panchpakhadi Savarkar Nagar, Thane, Maharashtra, India – 400606
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Alible Pharmaceutical is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Alible Pharmaceutical Private Limited, buy the company report.
Financials of Alible Pharmaceutical Private Limited
FY 2025 filings availableAlible Pharmaceutical Private Limited reported revenue of ₹11.22 Lakh (up 10% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 210% over three years, including 10% growth in the latest year. EBITDA fell 155% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | -₹34,574 | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹38,254 | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | -3.1% | |||
| Net Profit Margin | -3.4% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Alible Pharmaceutical Private Limited, buy the company report.
Board of directors of Alible Pharmaceutical Private Limited
Alible Pharmaceutical has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Dilip Bajarang Shinde Also directs: Dmerlin India Private Limited | Director | 05 Aug 2021 | 5 Years 3 Months | Current |
| Shivaji Ramesh Zodage Also directs: Dmerlin India Private Limited | Managing Director | 05 Aug 2021 | 5 Years 3 Months | Current |
Peer comparison
Alible Pharmaceutical Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Abvita Pharmaceuticals Private Limited | ₹11.28 Lakh (FY 2023) | -73.0% | Hyderabad, Telangana, India | |||
| Mohini Hygiene Care Products Private Limited | ₹11.25 Lakh (FY 2025) | -92.0% | Pithampur, Madhya Pradesh, India | |||
| Brit Allvin Pharmaceautical Private Limited | ₹11.25 Lakh (FY 2024) | 18.0% | Karnal, Haryana, India | |||
| Tejika Labs Private Limited | ₹11.25 Lakh (FY 2023) | 46.0% | Ankleshwar, Gujarat, India | |||
| Resalutem Pharmaceutical Private Limited | ₹11.22 Lakh (FY 2020) | 184.0% | Surat, Gujarat, India | |||
| Alible Pharmaceutical Private Limitedthis company | ₹11.22 Lakh (FY 2025) | -₹38,254 | -3.4% | 10.0% | Thane, Maharashtra, India | |
| Mahija Biofuel Industries Private Limited | ₹11.21 Lakh (FY 2023) | Ahmedabad, Gujarat, India | ||||
| Ignis Control Systems Private Limited | ₹11.2 Lakh (FY 2022) | 254.0% | Bangalore, Karnataka, India | |||
| Swabhi Pharma Private Limited | ₹11.2 Lakh (FY 2022) | 64.0% | Delhi, India | |||
| Ashoka Biotech Private Limited | ₹11.18 Lakh (FY 2023) | 107536250.0% | Bangalore, Karnataka, India | |||
| Arm Bioorganic Private Limited | ₹11.18 Lakh (FY 2019) | 154.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Alible Pharmaceutical Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Alible Pharmaceutical Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Alible Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Alible Pharmaceutical Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Alible Pharmaceutical Private Limited has 2 board changes on record since 2021: 2 appointments. The latest: Dilip Bajarang Shinde was appointed as Director on 05 Aug 2021.
Frequently asked questions
Alible Pharmaceutical is an active private limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 August 2021 (5+ years old) and is registered under CIN U24290MH2021PTC365379.
Alible Pharmaceutical has 2 current directors:
- Shivaji Ramesh Zodage - Managing Director
- Dilip Bajarang Shinde - Director
The latest financial statements of Alible Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2022 are in the company report.
The CIN (Corporate Identification Number) of Alible Pharmaceutical is U24290MH2021PTC365379. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Alible Pharmaceutical was incorporated on 05 August 2021, making it 5+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Alible Pharmaceutical by revenue are Abvita Pharmaceuticals Private Limited, Mohini Hygiene Care Products Private Limited, Brit Allvin Pharmaceautical Private Limited, Tejika Labs Private Limited, Resalutem Pharmaceutical Private Limited and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dilip Bajarang Shinde was appointed as Director on 05 Aug 2021. Shivaji Ramesh Zodage was appointed as Managing Director on 05 Aug 2021.
The registered office of Alible Pharmaceutical is at D5 Ashtavinayak Chs Plot No 4 Panchpakhadi Savarkar Nagar, Thane, Maharashtra, India – 400606.
Alible Pharmaceutical operates in the pharma industry, in the drug formulation and development segment.
Alible Pharmaceutical can be reached at its registered office: D5 Ashtavinayak Chs Plot No 4 Panchpakhadi Savarkar Nagar, Thane, Maharashtra, India – 400606.
Alible Pharmaceutical is registered under the jurisdiction of the Registrar of Companies (ROC), Mumbai.

